Pacific Biosciences Of California (PACB) Cash from Investing Activities Growth (5y) (2015 - 2026)
Pacific Biosciences Of California (PACB) Cash from Investing Activities Growth (5y) (2015 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Abbott Laboratories | 199.63 Bn | 194.02 Bn | 7.27 Bn |
| 2 | Stryker | 127.42 Bn | 123.95 Bn | 4.50 Bn |
| 3 | Medtronic | 118.97 Bn | 109.75 Bn | 6.41 Bn |
| 4 | Boston Scientific | 73.39 Bn | 72.85 Bn | 3.85 Bn |
| 5 | Edwards Lifesciences | 51.97 Bn | 47.72 Bn | 1.35 Bn |
| 6 | Dexcom | 34.32 Bn | 32.37 Bn | 830.00 Mn |
| 7 | GE HealthCare Technologies | 33.76 Bn | 31.65 Bn | 2.18 Bn |
| 8 | Koninklijke Philips | 26.35 Bn | 23.03 Bn | 4.55 Bn |
| 9 | Steris | 23.04 Bn | 22.56 Bn | 684.20 Mn |
| 10 | Pacific Biosciences Of California | 396.09 Mn | 159.21 Mn | 12.64 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 15.85% |
| Mar 31, 2026 | 34.42% |
| Dec 31, 2025 | 17.76% |
| Sep 30, 2025 | 18.10% |
| Jun 30, 2025 | 61.08% |
| Mar 31, 2025 | 23.15% |
| Dec 31, 2024 | 80.37% |
| Sep 30, 2024 | 3.25% |
| Jun 30, 2024 | 57.97% |
| Mar 31, 2024 | -23.72% |
| Dec 31, 2023 | -64.58% |
| Sep 30, 2023 | 53.38% |
| Jun 30, 2023 | -58.76% |
| Mar 31, 2023 | -56.42% |
| Dec 31, 2022 | 49.74% |
| Sep 30, 2022 | 61.66% |
| Jun 30, 2022 | -7.19% |
| Mar 31, 2022 | 10.54% |
| Dec 31, 2021 | 58.03% |
| Jun 30, 2021 | -118.94% |